fraxiparine solution for injection 7600iu
glaxosmithkline (ireland) limited - nadroparin calcium - solution for injection - 7600iu ant international unit
fraxiparine solution for injection 9500iu
glaxosmithkline (ireland) limited - nadroparin calcium - solution for injection - 9500iu ant international unit
fraxiparine inj
gsk - l m w h - inj - 8600i.u. (nadroparin)
fraxiparine iu 0.4ml ps inj
sanofi aventis - l m w h - inj - 4100 i.u.(nadroparin) - 0.4ml ps
fraxiparine iu 0.6ml ps inj
sanofi aventis - l m w h - inj - 6150 i.u.(nadroparin) - 0.6ml ps
fraxiparine iu 0.8mlps inj
sanofi aventis - l m w h - inj - 8600i.u. (nadroparin) - 0.8mlps
fraxiparine iuinj 0.3ml
sanofi aventis - l m w h - 3075 i.u.(nadroparin) - 0.3ml
fraxiparine forte
pharmacy retailing (nz) ltd t/a healthcare logistics - nadroparin calcium 19000 anti-xa iu/ml - solution for injection - 19000 anti-xa iu/ml - active: nadroparin calcium 19000 anti-xa iu/ml excipient: calcium hydroxide hydrochloric acid water for injection - treatment of deep vein thrombosis
fraxiparine 3800 iu axa/ 0.4 ml
glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.
fraxiparine 2850 iu axa/0.3 ml
glaxo smith kline (israel) ltd - nadroparin calcium 2850 iu / 0.3 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.